Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy

• المؤلفون الرئيسيون: Suthinee Ithimakin, Pathra Theeratrakul, Apirom Laocharoenkiat, Akarin Nimmannit, Charuwan Akewanlop, Nopadol Soparattanapaisarn, Sirisopa Techawattanawanna, Krittiya Korphaisarn, Pongwut Danchaivijitr
• مؤلفون آخرون: Faculty of Medicine, Siriraj Hospital, Mahidol University
• التنسيق: مقال
• منشور في: 2020
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://repository.li.mahidol.ac.th/handle/123456789/53805
• المؤسسة: Mahidol University

© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HE...